Small molecule inhibitors of the prostate cancer target KMT2D

被引:9
|
作者
Yu, Qi [1 ]
Liao, Zonglang [1 ]
Liu, Dan [1 ]
Xie, Wei [1 ]
Liu, Zhongqiu [1 ]
Liao, Guochao [1 ]
Wang, Caiyan [1 ]
机构
[1] Guangzhou Univ Chinese Med, Int Inst Translat Chinese Med, Guangdong Key Lab Translat Canc Res Chinese Med, Joint Lab Translat Canc Res Chinese Med,Minist Ed, Guangzhou 510006, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
KMT2D; Inhibitor; Prostate cancer; Molecular diversity; Drug design; H3K4; METHYLTRANSFERASE; MENIN; PROTEIN; FAMILY; GROWTH; GENE;
D O I
10.1016/j.bbrc.2020.09.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Histone lysine N-methyltransferase 2D (KMT2D), an important methyltransferase that is involved in the methylation of lysine 4 in histone H3 (H3K4) and related to the development of prostate cancer. Hypermethylation of H3K4 is shown in prostate cancer (PCa). However, KMT2D inhibitors have not yet been developed. This article aims to design small molecule inhibitors targeting KMT2D_SET to prevent PCa cell proliferation and migration. Twenty-four inhibitors were firstly designed according to a virtual screening of computers, and shown different degrees of binding to KMT2D_SET. Compounds 1 and 16 showed high binding affinities to KMT2D, with KD values of 147 +/- 32.9 mu M and 176 +/- 37.9 mu M, respectively. In addition, they exerted strong inhibitory activity against the PCa cell lines PC-3 and DU145, with IC50 values of 1.1 +/- 0.06 mu M, 1.5 +/- 0.06 mu M and 1.8 +/- 0.1 mu M, 2.3 +/- 0.2 mu M, respectively. Furthermore, these two compounds significantly suppressed the migration of PCa cells. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:540 / 547
页数:8
相关论文
共 50 条
  • [31] Absence of KMT2D/MLL2 mutations in abdominal paraganglioma
    Bilguvar, Kaya
    Goh, Gerald
    Korah, Reju
    Lifton, Richard P.
    Carling, Tobias
    CLINICAL ENDOCRINOLOGY, 2016, 84 (04) : 632 - 634
  • [32] Dissecting KMT2D missense mutations in Kabuki syndrome patients
    Cocciadiferro, Dario
    Augello, Bartolomeo
    De Nittis, Pasquelena
    Zhang, Jiyuan
    Mandriani, Barbara
    Malerba, Natascia
    Squeo, Gabriella M.
    Romano, Alessandro
    Piccinni, Barbara
    Verri, Tiziano
    Micale, Lucia
    Pasqualucci, Laura
    Merla, Giuseppe
    HUMAN MOLECULAR GENETICS, 2018, 27 (21) : 3651 - 3668
  • [33] Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promoters
    Wang, Naitao
    Pachai, Mohini R.
    Li, Dan
    Lee, Cindy J.
    Warda, Sarah
    Khudoynazarova, Makhzuna N.
    Cho, Woo Hyun
    Xie, Guojia
    Shah, Sagar R.
    Yao, Li
    Qian, Cheng
    Wong, Elissa W. P.
    Yan, Juan
    Tomas, Fanny V.
    Hu, Wenhuo
    Kuo, Fengshen
    Gao, Sizhi P.
    Luo, Jiaqian
    Smith, Alison E.
    Han, Ming
    Gao, Dong
    Ge, Kai
    Yu, Haiyuan
    Chandarlapaty, Sarat
    Iyer, Gopakumar V.
    Rosenberg, Jonathan E.
    Solit, David B.
    Al-Ahmadie, Hikmat A.
    Chi, Ping
    Chen, Yu
    NATURE GENETICS, 2025, 57 (01) : 165 - 179
  • [34] Assessing gene expression and methylation of KMT2D and IGF2 genes in patients with non-small cell lung cancer
    Matinahmadi, Arash
    Zayani, Zoofa
    Bidooki, Seyed Hesamoddin
    Tavakolpournegari, Alireza
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (06)
  • [35] KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer
    Alam, Hunain
    Tang, Ming
    Maitituoheti, Mayinuer
    Dhar, Shilpa S.
    Kumar, Manish
    Han, Chae Young
    Ambati, Chandrashekar R.
    Amin, Samir B.
    Gu, Bingnan
    Chen, Tsai-Yu
    Lin, Yu-Hsi
    Chen, Jichao
    Muller, Florian L.
    Putluri, Nagireddy
    Flores, Elsa R.
    DeMayo, Francesco J.
    Baseler, Laura
    Rai, Kunal
    Lee, Min Gyu
    CANCER CELL, 2020, 37 (04) : 599 - +
  • [36] KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes
    Sun, Peng
    Wu, Tong
    Sun, Xiaoliang
    Cui, Zilian
    Zhang, Haiyang
    Xia, Qinghua
    Zhang, Dong
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 115
  • [37] Immunologic assessment and KMT2D mutation detection in Kabuki syndrome
    Lin, J. -L.
    Lee, W. -I.
    Huang, J. -L.
    Chen, P. K. -T.
    Chan, K. -C.
    Lo, L. -J.
    You, Y. -J.
    Shih, Y. -F.
    Tseng, T. -Y.
    Wu, M. -C.
    CLINICAL GENETICS, 2015, 88 (03) : 255 - 260
  • [38] KMT2D loss cooperates with PTCH loss for medulloblastoma genesis
    Dhar, Shilpa S.
    Brown, Calena J.
    Rizvi, Ali S.
    Abraham, Janak R.
    Sillitoe, Roy V.
    Chen, Kaifu
    Lee, Min Gyu
    CANCER RESEARCH, 2022, 82 (12)
  • [39] Roles for MLL2/ KMT2D or MLL3/ KMT2C in HER+ breast cancer stem cells
    Zlobin, Andrei
    Wyatt, Debra
    Varsanik, Mary
    Dingwall, Andrew
    Osipo, Clodia
    CANCER RESEARCH, 2018, 78 (13)
  • [40] Investigating the potential relationship between KMT2C/KMT2D mutations and immune checkpoint inhibitor (ICI) in colorectal cancer (CRC)
    Miao, C.
    Zhang, X.
    Ma, T.
    Zhang, X.
    Zhu, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S451 - S451